Clinical Trials on B-cell Prolymphocytic Leukemia

Total 5692 results

Aptevo Therapeutics

Completed

Phase 1/1b Study of TRU-016 in Patients With Previously Treated CLL or Select Subtypes of Non-Hodgkin's Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Non-Hodgkin's Lymphoma (NHL)

United States
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Follicular Lymphoma | Multiple Myeloma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

United States
Wuhan Union Hospital, China
Beijing GoBroad Hospital Management Co.,Ltd; Shanghai YaKe Biotechnology Ltd.

Recruiting

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

T-Cell Lymphocytic Leukemia | T-Cell Chronic Lymphocytic Leukemia | T Cell Non-Hodgkin Lymphoma

China
Allogene Therapeutics

Recruiting

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2) (ALPHA2)

Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma

United States, Spain, Canada, Australia, Italy
Wang Xin

Recruiting

Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

CLL/SLL

China
iOMEDICO AG
AstraZeneca

Recruiting

Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO) (CICERO)

CLL

Germany
University of California, San Diego
Celgene Corporation

Completed

Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia | CLL

United States
Xinqiao Hospital of Chongqing
The First Affiliated Hospital of Anhui Medical University; Nanfang Hospital... and other collaborators

Unknown

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Acute Lymphoblastic Leukemia

China
Pharmacyclics LLC.

Completed

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Chronic Lymphocytic Leukemia | Small-Cell Lymphoma

United States, Australia, Austria, Belgium, Canada, Czechia, France, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Sweden, Turkey, United Kingdom
Boryung Pharmaceutical Co., Ltd

Active, not recruiting

BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I)

Follicular Lymphoma | B Cell Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Small Lymphocytic Leukemia

Korea, Republic of, United States
Shanghai Ming Ju Biotechnology Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University

Not yet recruiting

Phase I Study of JWCAR029 in Subjects With R/R CLL/SLL

Leukemia, Lymphocytic, Chronic, B-Cell

China
Rhizen Pharmaceuticals SA

Completed

Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Georgia, Bulgaria, Poland
AbbVie

Suspended

A Study to Describe the Effectiveness and Safety of Venetoclax Treatment in Chronic Lymphocytic Leukemia (CLL) Patients in Routine Clinical Practice (REVEAL)

Chronic Lymphocytic Leukemia (CLL)

Israel
AbbVie

Completed

A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent). (VENICE II)

Chronic Lymphocytic Leukemia (CLL)

Argentina, Australia, Bulgaria, Hong Kong, Hungary, Mexico, New Zealand, Poland, Russian Federation, Taiwan
Celgene
The Leukemia and Lymphoma Society

Completed

Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | B Cell Non-Hodgkin's Lymphoma

United States
New York Medical College

Completed

Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia (MITCL)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma | Acute Myelogenous Leukemia | Diffuse Large B-cell Lymphoma | Burkitt Lymphoma/Leukemia

United States
iOMEDICO AG

Recruiting

Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms (RUBIN)

Chronic Lymphocytic Leukemia (CLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL) | Waldenström's Macroglobulinemia (WM)

Germany
Sunesis Pharmaceuticals

Terminated

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Lymphoplasmacytoid Lymphoma

United States
Shenzhen Institute for Innovation and Translational...
Dongguan People's Hospital

Completed

Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Second Affiliated Hospital of Guangzhou Medical...
Guangzhou First People's Hospital; First People's Hospital of Foshan; Dongguan... and other collaborators

Unknown

A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

Lymphoma | Chronic Lymphocytic Leukemia | Acute Lymphocytic Leukemia

China
Leslie Andritsos
Celgene Corporation

Completed

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL (VIS)

Chronic Lymphocytic Leukemia | High Risk CLL

Italy
Sheba Medical Center

Unknown

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Acute Lymphoblastic Leukemia, B-precursor | Non-Hodgkin Lymphoma, B-cell

Israel
Wuhan Union Hospital, China
Wuhan Si'an Medical Technology Co., Ltd

Recruiting

Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

Follicular Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma

China
BeiGene

Recruiting

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Advanced Solid Tumor | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma

China, Australia
French Innovative Leukemia Organisation
Roche Pharma AG; Janssen-Cilag Ltd.

Completed

Phase II Trial GA101 Inbrutinib B CLL (ICLL07GAI)

Leukemia, Lymphocytic, Chronic, B-Cell

France
Arbeitsgemeinschaft medikamentoese Tumortherapie
Roche Pharma AG; Celgene Corporation

Completed

Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital; BeiGene USA, Inc.; Roche-Genentech

Recruiting

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

United States
German CLL Study Group
Cancer Trials Ireland; Stichting Hemato-Oncologie voor Volwassenen Nederland... and other collaborators

Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

Chronic Lymphoid Leukemia

Spain, Ireland, Austria, Denmark, Israel, Norway, Germany, Switzerland, Italy, Belgium, Finland, Sweden, Netherlands
AbbVie

Completed

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) (VENCLL regPMOS)

Cancer | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

Japan
Genentech, Inc.
AbbVie (prior sponsor, Abbott)

Completed

A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, United Kingdom
Hoffmann-La Roche

Terminated

A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status

Lymphocytic Leukemia, Chronic

Russian Federation
Hoffmann-La Roche

Terminated

A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status

Lymphocytic Leukemia, Chronic

Russian Federation
Hoffmann-La Roche

Completed

An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

France
Hoffmann-La Roche

Completed

An Observational Study on the Safety Profile of MabThera/Rituxan (Rituximab) in Combination With Chemotherapy in Patients With B Cell-lineage Chronic Lymphocytic Leukaemia (MABERYC)

Lymphocytic Leukemia, Chronic

Spain
Hoffmann-La Roche

Completed

An Observational Study on Infusion-related Adverse Events at Administration of MabThera (Rituximab) in Patients With Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

Sweden
Pharmacyclics LLC.

Terminated

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

Leukemia | Leukemia, Lymphocytic, Chronic

United States
BioCryst Pharmaceuticals

Completed

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic

United States
Sohag University

Not yet recruiting

ITGA4 Gene Methylation Status in Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Nanfang Hospital of Southern Medical University

Not yet recruiting

Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation

Chronic Lymphocytic Leukemia
National Taiwan University Hospital

Recruiting

Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Taiwan
Institute of Hematology & Blood Diseases Hospital

Recruiting

A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL (BDHCLL001)

Chronic Lymphocytic Leukemia

China
AbbVie

Completed

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) (VENICE I)

Chronic Lymphocytic Leukemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Norway, Portugal, Puerto Rico, Spain, Sweden, Switzerland, Turkey, United Kingdom
H. Lee Moffitt Cancer Center and Research Institute
TG Therapeutics, Inc.

Terminated

TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
University of Ulm
AbbVie; Roche Pharma AG; Janssen-Cilag Ltd.; German CLL Study Group

Completed

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL (CLL2-GiVe)

Leukemia, Lymphocytic, Chronic

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia

Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto
ERIC Group

Completed

Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study (LLC178)

Chronic Lymphocytic Leukemia

Italy
Grupo Espanol de trasplantes hematopoyeticos y...
GlaxoSmithKline

Completed

Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation

Chronic Lymphocytic Leukemia

Spain
Arbeitsgemeinschaft medikamentoese Tumortherapie
Mundipharma Pte Ltd.

Completed

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Austria
Italfarmaco

Terminated

Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Italy

Clinical Trials on B-cell Prolymphocytic Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations